Acumen Pharmaceuticals

Moat sources and durability today are weak because the company is pre‑revenue and dependent on a single asset.

Intangible assets: composition‑of‑matter and use patents for sabirnetug reportedly expire in 2031 (before extensions), and the drug would also benefit from 12‑year U.S. biologics data exclusivity if approved; however, the core IP is licensed from Merck and remains unproven commercially (score 40, weight 40%).

Switching costs: if Phase 2/3 demonstrate superior safety/efficacy, neurologists could show inertia, but payer step‑edits and registry requirements temper lock‑in (score 25, weight 20%). Network effects: none (score 0, weight 10%).

Cost advantage: large‑molecule manufacturing and MRI/monitoring infrastructure costs are high and scale benefits accrue to incumbents, not a small single‑asset biotech (score 10, weight 15%).

Efficient scale: the AD biologics market is huge, but capacity, diagnostics, and monitoring constraints may limit rapid uptake; incumbent relationships with centers of excellence favor first movers (score 25, weight 15%).

Weighted result ≈ 27/100. Key risks to moat formation: Phase 2 failure or non‑differentiated data; patent life/timing versus launch; and payer restrictions even with clinical success.